Transgene Biotek (BOM:526139) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 29, 2026)


BOM:526139 Transgene Biotek Ltd BOM:526139
47 GF Score
Price ₹3.11
GF Value ₹6.51
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Transgene Biotek Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Transgene Biotek's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BOM:526139 vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Transgene Biotek's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transgene Biotek Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene Biotek's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Transgene Biotek's Margin of Safety % (DCF Earnings Based) falls into.


BOM:526139
47GF Score
Transgene Biotek Ltd BOM:526139
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Transgene Biotek (BOM:526139) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene Biotek stock appears to be undervalued. The current stock price of ₹3.11 is trading 52.2% below its estimated GF Value™ of ₹6.51. GuruFocus considers Transgene Biotek to be Possible Value Trap.

Key valuation signals for BOM:526139:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: ₹6.51 vs. price of ₹3.11 (52.2% below fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the BOM:526139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Biotek Business Description

Address Anrich Industrial Area, Plot No. 69 and 70, IDA Bollaram, Sangareddy District, Medak, TG, IND, 502325
Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.
47GF Score

Get the complete analysis for BOM:526139

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3.11
Price
₹6.51
GF Value